Previous studies have demonstrated that both blinded and unblinded FGM can improve glycemic control in patients with type 2 diabetes (T2DM) compared with SMBG (5–7), and the main reason was that FGM guided the adjustment of insulin dosage or oral antidiabetic drugs in these patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.